Objective Whether to treat subclinical hypothyroidism (SH) 
Introduction

Subclinical hypothyroidism (SH) is a condition diagnosed when the serum thyroid stimulating hormone (TSH) level is above the reference value (0.45-4.5 mIU/L) and the free thyroid hormones are within normal levels (1, 2). The prevalence of SH has been reported to be between 4% and 10%
of adult population (3) (4) (5) . Whether to treat SH remains a dilemma (6, 7) . The decision to treat patients with SH is mainly based on the assessment of cardiac morbidity and mortality in patients with mild disease.
The relationship between SH and serum lipids remains controversial (8, 9) . Most studies on treatment with T4 have dealt only with surrogate markers. It is also uncertain whether SH is associated with increased cardiac risk mark-ers (10) . Four double-blind placebo randomized controlled trials found that replacement therapy may have a beneficial effect on lipid profile (11) (12) (13) . Replacement (14) . In a recent study, replacement therapy with L-thyroxine to normalize TSH did not modify t-Hyc levels in the fasting or postmethionine states in 24 patients with mild hypothyroidism (TSH levels between 5 and 10 mIU/L) (15) . T-Hyc levels were unaffected by the treatment of SH in three double-blind placebo-controlled studies (14, 15) .
therapy does not appear to affect lipoprotein a, homocysteine (t-Hyc) or C-reactive protein (CRP) (10). T4 replacement did not affect CRP levels in a double-blind placebo-controlled study in patients with SH
There is no report in the literature which shows thyroid replacement therapy increases cardiac risk factors. We know that in some patients, however, increased metabolic demands on the heart can cause a clinical demasking of a previously compensated preexisting ischemic heart disease (16) , Keating et al (17) (18) .
Human chitotriosidase (ChT) is a recently described fully active chitinase expressed by activated macrophages (19) . ChT was first discovered in plasma of patients suffering from Gaucher disease (20) (24) . T a b l e 1 . Co mp a r i s o n o f Cl i n i c a l a n d L a b o r a t o r y P a r a me t e r s b e (27) . 
Modulation of the immune response by thyroid hormones has been well recognized for years. It is unclear whether they play a significant role in T lymphocyte development and cell-mediated immunity (25). Thus, the aim of this study was to assess the impact of correcting SH with levothyroxine on biochemical risk factors (such as ChT, sCRP and t-Hyc) of cardiovascular diseases.
Materials and Methods
Study subjects
t we e n P a t i e n t s wi t h S u b c l i n i c a l Hy p o t h y r o i d i s m a n d t h e Co n t r o l Gr
. In the quantitative method, the fluorescence of 4 methylumbelliferon was read in a Microfluor 2 plate by a fluorimeter (BIO-TEK SynergyHT; Biotek Instruments Inc., Winooski, VT) (excitation 360, emission 450 nm). The ChT activity was expressed as nanomols of substrate hydrolyzed per milliliter per hour (nmol/mL/h). Reference range of plasma ChT (4-195 nmol/mL/h) was used as described by Guo et al
Statistics
Database management and all statistical analyses were performed by using SPSS for windows (version 15.0, SPSS, Chicago, IL, USA). Results are expressed as mean ± SD. P values of <0.05 were considered significant. As some variables including Cht were not distributed normally as checked by histograms and Kolmogorov-Smirnoff test, nonparametric testing for further analysis was employed. Differences were tested with the non-parametric
Results
The main findings of controls and patients are given in Table 1 . There were no significant difference in sex, body T a b l e 2 . An a l y s e s o f L a b o r a t o r y P a r a me t e r s b e f o r e a n d a f t e r L e v o t h y r o (Fig. 1) .
ChT increament did not differ according to smoking and menopause status (data not included).
There was a significant correlation between ChT levels, or ChT change during therapy, and other laboratory parameters. Basal ChT levels in subclinical hypothyroidism were greater than the control group (p>0.05).
Discussion
The main finding of the present study is that restoration of euthyroidism did not significantly modify LDL cholesterol, t-Hyc, and hsCRP levels, which are known as cardiovascular risk factors, in patients with SH. However, ChT levels were significantly increased after euthyroidism, which is a new cardiovascular risk marker.
There is still doubt whether or not replacement therapy lowers serum lipid levels in patients with SH (10) . Homocysteine levels were unaffected by the treatment of SH in double-blind placebo-controlled studies (14, 15 
F i g u r e 1 . Ch i t o t r i o s i d a s e a c t i v i t y l e v e l s o f p a t i e n t s a t b a s e l i n e a n d p o s t -t r e a t me n t a n d h e a l t h y c o n t r o l s .
or to another mechanism whereby thyroid hormone increases macrophage activation (30) . Thyroid hormones are known to affect cell-mediated immune response (31) . Cht is viewed as a component of innate immunity (32) . Thyroxine may increase the cellular immune response. More detailed studies are needed into this.
Among elderly patients, the mean annual mortality rate was lower in those with subclinical hypothyroidism compared to both those with low and normal TSH levels in one study (33) . Also in another recent report, SH was associated with a significantly better outcome in patients with acute stroke (34) . Chitotriosidase was found to be directly correlated with stroke severity independently of preexisting inflammatory or infectious conditions (35) .
More clinical trials are needed to assess whether T4 replacement reduces the risk of coronary heart disease in subjects with subclinical thyroid disease.
In 
